NEW YORK(GenomeWeb) – Australian proteomics firm Proteomics International Laboratories today said it plans to offer up to A$6 million (US$5.2 million) of its shares in an initial public offering on the Australian Stock Exchange.

The firm said in a prospectus that it seeks to raise between A$4 million and A$6 million through an offering of up to 30 million shares of its stock at A$.20 per share. The proceeds will be used to drive growth in each of its three business units: analytical services, diagnostics, and therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.